AR093758A1 - Inhibidores de aril lactama quinasa - Google Patents
Inhibidores de aril lactama quinasaInfo
- Publication number
- AR093758A1 AR093758A1 ARP130102716A ARP130102716A AR093758A1 AR 093758 A1 AR093758 A1 AR 093758A1 AR P130102716 A ARP130102716 A AR P130102716A AR P130102716 A ARP130102716 A AR P130102716A AR 093758 A1 AR093758 A1 AR 093758A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- haloalkyl
- 3amino
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1) o una sal de aquel aceptable desde el punto de vista farmacéutico, en donde R¹ se selecciona de hidrógeno, alquenilo C₂₋₄, alcoxi C₁₋₃, alcoxi C₁₋₃alquilo C₁₋₃, alquilo C₁₋₃, alquil C₁₋₃amino, arilalquilo C₁₋₃, cicloalquilo C₃₋₆, cicloalquil C₃₋₆alquilo C₁₋₃, haloalquilo C₁₋₃ y hidroxialquilo C₁₋₃; R² se selecciona de hidrógeno, alcoxi C₁₋₃, alcoxi C₁₋₃carbonilamino, alquilo C₁₋₃, alquil C₁₋₃amino, alquil C₁₋₃carbonilamino, amino, arilamino, arilcarbonilamino, cicloalquil C₃₋₆amino, cicloalquil C₃₋₆carbonilamino, cicloalquiloxi C₃₋₆, halo, haloalcoxi C₁₋₃, haloalquilo C₁₋₃, haloalquil C₂₋₃amino, haloalquil C₂₋₃carbonilamino, hidroxi y fenil-alquil C₁₋₃amino, en donde el fenilo se sustituye opcionalmente con un grupo alcoxi C₁₋₃; R³ y R⁴ se seleccionan independientemente de hidrógeno, alcoxi C₁₋₄, alcoxi C₁₋₃alquilo C₁₋₃, alcoxi C₁₋₃carbonilo, alquilo C₁₋₄, alquil C₁₋₃sulfonilo, aminocarbonilo, ciano, cicloalquilo C₃₋₆, di(alquil C₁₋₃)aminocarbonilo, halo, haloalcoxi C₁₋₃, haloalquilo C₁₋₃, heteroarilo, hidroxi, hidroxialquilo C₁₋₃ y fenilo opcionalmente sustituido con un grupo halo; R⁵ es alquil C₁₋₃-Y o alquilo C₂₋₈, en donde alquilo C₂₋₈ se sustituye opcionalmente con 1, 2, 3 ó 4 grupos seleccionados independientemente de alcoxi C₁₋₃, alquil C₁₋₃amino, alcoxi C₁₋₃alquil C₂₋₃amino, amino, arilo, di(alquil C₁₋₃)amino, halo, haloalquil C₁₋₃amino, haloalquil C₁₋₃carbonilamino, hidroxi, -NRˣRʸ y cicloalquilo C₃₋₈, en donde el cicloalquilo también se sustituye opcionalmente con 1, 2 ó 3 grupos seleccionado independientemente de alcoxi C₁₋₃, alquilo C₁₋₃, alquil C₁₋₃amino, alcoxi C₁₋₃alquil C₂₋₃amino, amino, arilo, arilalquilo C₁₋₃, halo, haloalquilo C₁₋₃, haloalquil C₁₋₃amino e hidroxi; Rˣ y Rʸ, junto con el átomo de nitrógeno al que están unidos, forman un anillo de 3 a 6 miembros; e Y se selecciona del grupo de fórmulas (2); en donde n es 0, 1, 2 ó 3; cada R⁶ se selecciona independientemente de hidrógeno, alquilo C₁₋₆, arilo, arilalquilo C₁₋₃, cicloalquilo C₃₋₆, halo y haloalquilo C₁₋₃; cada R⁷ se selecciona independientemente de hidrógeno, alcoxi C₁₋₃ e hidroxi; y R⁸ se selecciona de hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆ y alquil C₁₋₆carbonilo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261677856P | 2012-07-31 | 2012-07-31 | |
| US13/946,344 US8901305B2 (en) | 2012-07-31 | 2013-07-19 | Aryl lactam kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093758A1 true AR093758A1 (es) | 2015-06-24 |
Family
ID=50026068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102716A AR093758A1 (es) | 2012-07-31 | 2013-07-31 | Inhibidores de aril lactama quinasa |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8901305B2 (es) |
| EP (1) | EP2880032B1 (es) |
| JP (1) | JP2015528018A (es) |
| CN (1) | CN104507941A (es) |
| AR (1) | AR093758A1 (es) |
| BR (1) | BR112015001890A2 (es) |
| CA (1) | CA2880523A1 (es) |
| EA (1) | EA201590268A1 (es) |
| ES (1) | ES2602965T3 (es) |
| MX (1) | MX2015000980A (es) |
| TW (1) | TW201410676A (es) |
| WO (1) | WO2014022167A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105121445A (zh) | 2013-02-22 | 2015-12-02 | 百时美施贵宝公司 | 作为连接蛋白相关激酶1(AAK1)抑制剂的5H-色烯并[3,4-c]吡啶 |
| US10253027B2 (en) | 2013-07-08 | 2019-04-09 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| CN105979950A (zh) | 2013-10-11 | 2016-09-28 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| JP6276865B2 (ja) * | 2014-01-29 | 2018-02-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アリールラクタムキナーゼ阻害剤 |
| ES2700549T3 (es) | 2014-04-02 | 2019-02-18 | Bristol Myers Squibb Co | Inhibidores de biaril quinasa |
| US10174044B2 (en) * | 2015-04-10 | 2019-01-08 | Bristol-Myers Squibb Company | Fused pyridines as kinase inhibitors |
| US10544120B2 (en) | 2015-10-01 | 2020-01-28 | Bristol-Myers Squibb Company | Biaryl kinase inhibitors |
| JP6864674B2 (ja) * | 2015-10-01 | 2021-04-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ビアリールキナーゼ阻害剤 |
| CN114853664B (zh) * | 2022-06-02 | 2023-09-29 | 河南大学 | 一种钯催化条件下合成α,β-不饱和杂环己基酮类化合物的方法 |
| CN116102542A (zh) * | 2023-02-15 | 2023-05-12 | 如东众意化工有限公司 | 环丙唑醇精制母液中环丙唑醇的回收方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| JP3100984B2 (ja) | 1992-12-02 | 2000-10-23 | ファイザー・インク． | 選択的ｐｄｅ▲下ｉ▼▲下ｖ▼阻害物質としてのカテコールジエーテル類 |
| US5709861A (en) | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| ES2301793T3 (es) | 2002-04-05 | 2008-07-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Cianamidas utiles como inhibidores reversibles de cisteina proteasas. |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| US7601868B2 (en) | 2003-02-12 | 2009-10-13 | Takeda Pharmaceutical Company Limited | Amine derivative |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| JP2007523109A (ja) * | 2004-02-18 | 2007-08-16 | エフ．ホフマン−ラ ロシュ アーゲー | 複素環式Ｇａｂａ−Ａサブタイプ選択的レセプターモジュレーター |
| US20050288338A1 (en) | 2004-06-24 | 2005-12-29 | Wenqing Yao | Amido compounds and their use as pharmaceuticals |
| CN100494167C (zh) | 2005-08-02 | 2009-06-03 | 天津大学 | 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用 |
| AU2006326247A1 (en) * | 2005-12-15 | 2007-06-21 | F. Hoffmann-La Roche Ag | Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents |
| JP2007217408A (ja) | 2006-01-19 | 2007-08-30 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| BRPI0708644A2 (pt) * | 2006-03-07 | 2011-06-07 | Bristol-Myers Squibb Company | compostos de pró-fármaco de anilina de pirrolotriazina úteis como inibidores de cinase |
| RU2451018C2 (ru) | 2006-04-07 | 2012-05-20 | Вертекс Фармасьютикалз Инкорпорейтед | Модуляторы атф-связывающих кассетных транспортеров |
| US20080039535A1 (en) | 2006-08-14 | 2008-02-14 | Wyeth | Methods of identifying agents for treating neurological disorders |
| JP2010514689A (ja) * | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物 |
| US20100292281A1 (en) * | 2009-05-15 | 2010-11-18 | The University Of Kentucky Research Foundation | Treatment of mci and alzheimer's disease |
| FR2955109B1 (fr) * | 2010-01-08 | 2012-09-07 | Sanofi Aventis | Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique |
| US8791257B2 (en) * | 2010-03-31 | 2014-07-29 | Bristol-Myers Squibb Company | Substituted pyrrolotriazines as protein kinase inhibitors |
| US8703953B2 (en) | 2012-03-09 | 2014-04-22 | Bristol-Myers Squibb Company | Aryl ether-base kinase inhibitors |
| NZ630721A (en) | 2012-03-09 | 2016-12-23 | Lexicon Pharmaceuticals Inc | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use |
| EP3235499A3 (en) | 2012-03-09 | 2018-01-17 | Lexicon Pharmaceuticals, Inc. | Inhibition of adaptor associated kinase 1 for the treatment of pain |
| ES2676826T3 (es) | 2012-03-09 | 2018-07-25 | Lexicon Pharmaceuticals, Inc. | Compuestos basados en imidazo[1,2-b]piridazina, composiciones que los comprenden y usos de los mismos |
-
2013
- 2013-07-19 US US13/946,344 patent/US8901305B2/en active Active
- 2013-07-24 CN CN201380041073.9A patent/CN104507941A/zh active Pending
- 2013-07-24 CA CA2880523A patent/CA2880523A1/en not_active Abandoned
- 2013-07-24 EP EP13744927.8A patent/EP2880032B1/en active Active
- 2013-07-24 JP JP2015525460A patent/JP2015528018A/ja not_active Withdrawn
- 2013-07-24 MX MX2015000980A patent/MX2015000980A/es unknown
- 2013-07-24 WO PCT/US2013/051831 patent/WO2014022167A1/en active Application Filing
- 2013-07-24 BR BR112015001890A patent/BR112015001890A2/pt not_active Application Discontinuation
- 2013-07-24 ES ES13744927.8T patent/ES2602965T3/es active Active
- 2013-07-24 EA EA201590268A patent/EA201590268A1/ru unknown
- 2013-07-30 TW TW102127296A patent/TW201410676A/zh unknown
- 2013-07-31 AR ARP130102716A patent/AR093758A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201410676A (zh) | 2014-03-16 |
| EP2880032A1 (en) | 2015-06-10 |
| US20140038999A1 (en) | 2014-02-06 |
| ES2602965T3 (es) | 2017-02-23 |
| CN104507941A (zh) | 2015-04-08 |
| EA201590268A1 (ru) | 2015-05-29 |
| JP2015528018A (ja) | 2015-09-24 |
| US8901305B2 (en) | 2014-12-02 |
| BR112015001890A2 (pt) | 2017-07-04 |
| MX2015000980A (es) | 2015-04-10 |
| EP2880032B1 (en) | 2016-10-05 |
| CA2880523A1 (en) | 2014-02-06 |
| WO2014022167A1 (en) | 2014-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR098872A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR110405A1 (es) | Compuestos | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR093515A1 (es) | Triazolopirazinas | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| AR093579A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| AR088630A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR087909A1 (es) | Composiciones farmaceuticas | |
| AR099495A1 (es) | Derivados de amida, antagonistas de orexina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |